[Effects of proteasome inhibitor bortezomib on NF-kappaB activity and ICAM-1 mRNA expression of K562 cells].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
; 16(5): 1006-9, 2008 Oct.
Article
em Zh
| MEDLINE
| ID: mdl-18928584
ABSTRACT
This study was aimed to investigate the effects of proteasome inhibitor bortezomib (Velcade, PS-341) on the activation of NF-kappaB and the expression of intercellular adhesion molecule-1 (ICAM-1) in K562 cells. The K562 cells were incubated in the culture of RPMI 1640 with 10% calf serum in 12-well plates and exposed to 0, 10, 20, 30, 50 and 100 nmol/L of bortezomib for 6 hours. The activation of NF-kappaB was analyzed by SP immunohistochemistry, meanwhile RT-PCR was performed to detect expression of ICAM-1. The results showed that the activation of NF-kappaB and the expression of ICAM-1 in K562 cells decreased significantly after bortezomib treatment. The inhibitory effect on ICAM-1 was probably related with the activity suppression of NF-kappaB. It is concluded that proteasome inhibitor bortezomib downregulates the expression of K562 cell ICAM-1 by inhibiting the activity of NF-kappaB, which provides a new way for the target therapy in acute leukemia.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Inibidores de Proteases
/
Pirazinas
/
Ácidos Borônicos
/
NF-kappa B
/
Molécula 1 de Adesão Intercelular
Limite:
Humans
Idioma:
Zh
Revista:
Zhongguo Shi Yan Xue Ye Xue Za Zhi
Assunto da revista:
HEMATOLOGIA
Ano de publicação:
2008
Tipo de documento:
Article
País de afiliação:
China